<SEC-DOCUMENT>0001564590-20-029427.txt : 20200616
<SEC-HEADER>0001564590-20-029427.hdr.sgml : 20200616
<ACCEPTANCE-DATETIME>20200616071026
ACCESSION NUMBER:		0001564590-20-029427
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20200612
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200616
DATE AS OF CHANGE:		20200616

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		20964966

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-8k_20200612.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-06-16T09:58:55.8158643+00:00 -->
<!-- Version            : 5.0.1.463 -->
<!-- Package ID         : f119af81f994498bbd392498592b9f45 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nbix="http://www.neurocrine.com/20200612" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
nbix-8k_20200612.htm
</title>
</head>
<!-- NG Converter v5.0.2.46 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000914475_20200612_20200612">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000914475_20200612_20200612">0000914475</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="nbix-20200612.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000914475_20200612_20200612">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-12</xbrli:startDate>
					<xbrli:endDate>2020-06-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p></div>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000914475_20200612_20200612">8-K</ix:nonNumeric> </p></div>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000914475_20200612_20200612" format="ixt:datemonthdayyearen">June 12, 2020</ix:nonNumeric></p></div>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000914475_20200612_20200612">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p></div>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:34%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000914475_20200612_20200612" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000914475_20200612_20200612">0-22705</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000914475_20200612_20200612">33-0525145</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:34%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:34%;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:67%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000914475_20200612_20200612">12780 El Camino Real</ix:nonNumeric>,</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000914475_20200612_20200612">San Diego</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000914475_20200612_20200612" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p>
<p style="line-height:2pt;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000914475_20200612_20200612">92130</ix:nonNumeric></p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:67%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p>
<p style="line-height:2pt;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000914475_20200612_20200612">858</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000914475_20200612_20200612">617-7600</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:34.17%;"></td>
<td style="width:1.02%;"></td>
<td style="width:5.38%;"></td>
<td style="width:24.26%;"></td>
<td style="width:1.02%;"></td>
<td style="width:34.16%;"></td>
</tr>
<tr>
<td colspan="6" valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000914475_20200612_20200612">Common Stock, $0.001 par value</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000914475_20200612_20200612">NBIX</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000914475_20200612_20200612" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000914475_20200612_20200612" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000914475_20200612_20200612" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000914475_20200612_20200612" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000914475_20200612_20200612" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000914475_20200612_20200612" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:6pt;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:Segoe UI Symbol;"><span style="font-size:10pt;font-family:'Times New Roman'">&#9744;</span></span></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entry into a Material Definitive Agreement</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:8.67%;text-indent:-8.67%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exclusive License Agreement</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 12, 2020 (the &#8220;<span style="font-weight:bold;font-style:italic;">Agreement Date</span>&#8221;), Neurocrine Biosciences, Inc. (the &#8220;<span style="font-weight:bold;font-style:italic;">Company</span>&#8221;) entered into an Exclusive License Agreement (the &#8220;<span style="font-weight:bold;font-style:italic;">License Agreement</span>&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;<span style="font-weight:bold;font-style:italic;">Takeda</span>&#8221;) for the development and commercialization of various compounds encompassing the following seven assets (collectively, the &#8220;<span style="font-weight:bold;font-style:italic;">Licensed Products</span>&#8221;): (i) TAK-831 for schizophrenia (the &#8220;<span style="font-weight:bold;font-style:italic;">Phase II Asset</span>&#8221;), (ii) TAK-653 for treatment-resistant depression (the &#8220;<span style="font-weight:bold;font-style:italic;">TAK-653 Program</span>&#8221;), (iii) TAK-041 for anhedonia (the &#8220;<span style="font-weight:bold;font-style:italic;">TAK-041 Program</span>&#8221; and together with the TAK-653 Program, the &#8220;<span style="font-weight:bold;font-style:italic;">Phase II Ready Assets</span>&#8221;), and (iv) four non-clinical stage assets (the &#8220;<span style="font-weight:bold;font-style:italic;">Non-Clinical Assets</span>&#8221;). </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">License. <span style="font-style:normal;">Under the License Agreement, upon the expiration or termination of applicable waiting periods and the receipt of any required approvals or clearances under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (such date, the &#8220;</span><span style="font-weight:bold;">Effective Date</span><span style="font-style:normal;">&#8221; and such clearance, &#8220;</span><span style="font-weight:bold;">Antitrust Clearance</span><span style="font-style:normal;">&#8221;), Takeda has agreed to grant, as of the Effective Date, exclusive, non-transferable, sublicensable licenses to certain of Takeda&#8217;s intellectual property rights in all fields of use on a worldwide basis to develop, manufacture and commercialize the Licensed Assets.&#160;&#160;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Profit and Loss Sharing Options. <span style="font-style:normal;">As of the Effective Date, the Phase II Asset will be deemed a royalty-bearing product under the License Agreement pursuant to which the Company will be responsible for all costs and expenses associated with the development, manufacture and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset (a &#8220;</span><span style="font-weight:bold;">Royalty-Bearing Product</span><span style="font-style:normal;">&#8221;), and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which the Company and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties (a &#8220;</span><span style="font-weight:bold;">Profit-Share Product</span><span style="font-style:normal;">&#8221;).&#160;&#160;Subject to specified conditions, Takeda may elect to exercise such opt-in right for the Phase II Asset before the Company initiates a Phase III clinical trial for such Phase II Asset.&#160;&#160;As of the Effective Date, each of the Phase II Ready Assets will be deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset.&#160;&#160;In addition, under certain circumstances related to the development and commercialization activities to be performed by the Company, Takeda may elect to opt-out of the profit sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which the Company will be responsible for all costs and expenses associated with the development, manufacture and commercialization of such assets, subject to certain exceptions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development Plans and Diligence Obligations.<span style="font-style:normal;">&#160;&#160;For each Licensed Product, except as otherwise agreed by the parties in writing, the Company will be principally responsible for performing all development activities.&#160;&#160;The parties will establish a joint steering committee (the &#8220;</span><span style="font-weight:bold;font-style:normal;">JSC</span><span style="font-style:normal;">&#8221;) that will monitor and provide strategic oversight of the activities under the License Agreement.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will use commercially reasonable efforts to develop and seek regulatory approval and, as applicable, pricing approval for (i) at least one Licensed Product that comprises a Phase II Ready Asset and at least one Licensed Product that comprises a Phase II Asset, in each case, in each of the United States, Japan, the European Union, and the United Kingdom (the &#8220;<span style="font-weight:bold;font-style:italic;">Major Markets</span>&#8221;) and (ii) at least one Licensed Product that comprises a Non-Clinical Asset in each of two specified Target Classes (as defined below), in each case, in at least one Major Market. </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda will be solely responsible for conducting the two ongoing Phase II clinical trials currently being conducted by Takeda (&#8220;<span style="font-weight:bold;font-style:italic;">Phase II Ongoing Trials</span>&#8221;) with an option to fund, on an equal basis with the Company, any additional Phase II clinical trials that are necessary to advance the Phase II Asset to Phase III clinical trials, subject to specified conditions. Takeda will use commercially reasonable efforts to conduct the Phase II Ongoing Trials and all associated Phase II ongoing activities.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financial Terms.<span style="font-style:normal;"> Under the terms of the License Agreement, the Company has agreed to pay Takeda an upfront payment of $120.0 million (minus an earnest money deposit already paid by the Company to Takeda) within five business days after the Effective Date. In addition, Takeda will be entitled to development milestones of up to $495.0 million in the aggregate and commercial milestones of up to $1.4 billion in the aggregate for Royalty-Bearing Products.&#160;&#160;The Company has also agreed to pay Takeda royalties up to high-teen percentage rates based upon sales tiers on future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country (the &#8220;</span><span style="font-weight:bold;">Royalty Term</span><span style="font-style:normal;">&#8221;). </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Termination.<span style="font-style:normal;"> Unless earlier terminated, the License Agreement will continue on a Licensed Product-by-Licensed Product and country-by-country basis until the date on which, (i) for any Royalty-Bearing Product, the Royalty Term has expired in such country&#59; and (ii) for any Profit-Share Product, for so long as the Company continues to develop, manufacture or commercialize such Licensed Product (collectively, the &#8220;</span><span style="font-weight:bold;">Term</span><span style="font-style:normal;">&#8221;).&#160;&#160;The Company may terminate the License Agreement for convenience in its entirety or in one or more (but not all) of the Major Markets on six months&#8217; written notice to Takeda (i) with respect to all Licensed Products prior to the first commercial sale of the first Licensed Product for which first commercial sale occurs, or (ii) with respect to all Licensed Products in </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">one or more given Target Classes prior to the First Commercial Sale of the first Licensed Product in such Target Class(es) for which first commercial sale occurs.&#160;&#160;&#8220;</span><span style="font-weight:bold;">Target Classes</span><span style="font-style:normal;">&#8221; means the group of all Licensed Products that share a certain mechanism of action.&#160;&#160;The Company may terminate the License Agreement for convenience in its entirety or in one or more (but not all) of the Major Markets on 12 months&#8217; written notice to Takeda (i) with respect to all Licensed Products following the first commercial sale of the first Licensed Product for which first commercial sale occurs, or (ii) with respect to all Licensed Products in one or more given Target Classes following the first commercial sale of the first Licensed Product in such Target Class(es) for which first commercial sale.&#160;&#160;Takeda may terminate the License Agreement, subject to specified conditions, (i) if the Company challenges the validity or enforceability of certain Takeda intellectual property rights or (ii) on a Target Class-by-Target Class basis, in the event that the Company does not conduct any material development or commercialization activities with respect to any Licensed Product within such Target Class for a specified continuous period. Subject to a cure period, either party may terminate the License Agreement in the event of any material breach, solely with respect to the Target Class of a Licensed Product to which such material breach relates, or in its entirety in the event of any material breach that relates to all Licensed Products. Either party may also terminate the License Agreement if the parties are unable to obtain Antitrust Clearance within 120 days of the Agreement Date and the parties have not agreed in writing to extend the Antitrust Clearance date. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the terms of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement, a copy of which will be filed with the Securities and Exchange Commission as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements </p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect the Company&#8217;s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent the Company&#8217;s estimates and assumptions only as of the date of this Current Report on Form 8-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:89%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:89%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;color:#0563C1;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nbix-ex991_17.htm"><span style="text-decoration:underline;">Press Release dated June 16, 2020</span></a></p></td>
</tr>
<tr style="height:4.95pt;">
<td valign="bottom" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr style="height:17.55pt;">
<td valign="bottom" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><br /><br /><br /><br /><br /><br /><br /></p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NEUROCRINE BIOSCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: June 16, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Darin M. Lippoldt</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-top:solid 0.75pt #000000;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Darin M. Lippoldt</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix-ex991_17.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nbix-ex991_17.htm
</title>
</head>
<!-- NG Converter v5.0.2.46 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Century;font-size:10.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcjj3cauwzyv000001.jpg" title="" alt="" style="width:212px;height:52px;"><font style="margin-left:41pt;"><img src="gcjj3cauwzyv000002.jpg" title="" alt="" style="width:118px;height:57px;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="line-height:17pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk10195680"></a><a name="_Hlk10195216"></a><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize  Potential Therapies for Psychiatric Disorders</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8722;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS PMincho;font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within Takeda&#8217;s Neuroscience portfolio</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8722;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS PMincho;font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Collaboration includes three clinical-stage assets with the most advanced molecule in Phase II for negative symptoms of schizophrenia</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:MS PMincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8722;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS PMincho;font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Takeda retains ability to opt in or out of a 50:50 profit share on all clinical programs at certain development events</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SAN DIEGO and Osaka, Japan, June 16, 2020 &#8211; <font style="font-weight:normal;">Neurocrine Biosciences, Inc. (</font><font style="text-decoration:underline;font-weight:normal;">Nasdaq: NBIX</font><font style="font-weight:normal;">) and Takeda Pharmaceutical Company Limited (</font><font style="letter-spacing:0.5pt;text-decoration:underline;font-weight:normal;">TSE:4502/NYSE:TAK</font><font style="font-weight:normal;">) (&#8220;Takeda&#8221;) today announced a strategic collaboration to develop and commercialize compounds in Takeda&#8217;s early-to-mid-stage psychiatry pipeline. Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.</font></p>
<p style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are excited to collaborate with Takeda to bring life-changing therapies to people living with serious, challenging and under-addressed psychiatric disorders who are in need of better treatment options,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer at Neurocrine Biosciences. &#8220;With our deep understanding in the fields of psychiatry and neurology, we look forward to developing new treatments for schizophrenia, treatment-resistant depression and anhedonia as part of our diverse clinical development pipeline. This strategic partnership enhances our growing pipeline and strengthens our position as a leading neuroscience-focused biopharmaceutical company.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;With longstanding experience developing and commercializing therapies for serious neurological and psychiatric disorders, Neurocrine Biosciences is the ideal partner to continue to develop our early-to-mid-stage psychiatry portfolio and bring these potential new therapies to patients,&#8221; said Sarah Sheikh, M.D., M.Sc., MRCP, Head, Neuroscience Therapeutic Area Unit at Takeda. &#8220;Takeda is deeply committed to Neuroscience as one of our core therapeutic areas. The strategic partnership with Neurocrine Biosciences allows us to continue to build on our leadership in psychiatry and deliver future medicines for these patients while advancing our clinical assets for rare neurological diseases, such as narcolepsy, developmental and epileptic encephalopathies and neurodegenerative conditions.&#8221; </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk40600858"></a><br /></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:8.52%;"><font style="margin-left:41pt;"></font>1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Century;font-size:10.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:8.52%;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Details</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk41301732"></a>Under the terms of the agreement, Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration. Takeda will receive a total of $120 million USD in upfront cash. Additionally, Takeda will be entitled to development milestones of up to $495 million USD, commercial milestones of up to $1.4 billion USD and up to double-digit royalties on net sales. At certain development events, Takeda may elect to opt in or out of a 50:50 profit share on all clinical programs on an asset-by-asset basis.<a name="_Hlk41301732"></a> For any asset in which Takeda is participating in a 50:50 profit share arrangement, Takeda will not be eligible to receive development or commercial milestones. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conference Call Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Today, Neurocrine Biosciences will host a conference call and webcast at 8:00 a.m. ET to provide commentary on the collaboration. The live call may be accessed by dialing (866) 831-8711 (U.S.) or (203) 518-9883 (International) using the conference ID: 5022. A live audio webcast of the conference call will be available online on the Neurocrine Bioscience website under Investors at <font style="text-decoration:underline;color:#000000;">www.neurocrine.com.</font> A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Programs in the Collaboration Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TAK-831</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TAK-831 is a potential first-in-class D-Amino Acid Oxidase (DAAO) inhibitor that has completed multiple Phase I studies and is currently in on-going Phase II studies, including the Phase II INTERACT proof-of-concept study in negative symptoms of schizophrenia.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TAK-653</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TAK-653 is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) potentiator. TAK-653 has completed Phase I studies and is a Phase II study-ready compound with the potential to be developed for treatment-resistant depression.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TAK-041</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TAK-041 is a potential first-in-class G Protein-Coupled Receptor 139 (GPR139) agonist. TAK-041 has completed multiple Phase I studies and is a Phase II study-ready compound with the potential to be developed for the treatment of anhedonia in depression. Anhedonia is a psychological condition characterized by the inability to experience pleasure.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preclinical Programs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration includes the rights to four preclinical programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Neurocrine Biosciences</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:8.52%;"><font style="margin-left:41pt;"></font>2</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#8217;s disease endometriosis* and </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uterine fibroids* and </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical development programs in multiple therapeutic areas including a gene therapy for Parkinson&#8217;s disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information, visit </font><font style="text-decoration:underline;">neurocrine.com</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and follow the company on </font><font style="text-decoration:underline;">LinkedIn</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. (*in collaboration with AbbVie)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Takeda&#8217;s Commitment to Neuroscience</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda&#8217;s Neuroscience therapeutic area is driven by the immense unmet need of patients suffering from neurological diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these patients. Our commitment to patients extends beyond our research and development efforts by supporting several neuroscience patient and provider organizations to raise awareness, educate and broaden access to therapies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">About Takeda Pharmaceutical Company Limited</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Takeda Pharmaceutical Company Limited (</font><font style="text-decoration:underline;color:#000000;">TSE:4502/NYSE:TAK</font><font style="Background-color:#FFFFFF;">) is a global, values-based, R&amp;D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&amp;D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&amp;D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&amp;D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit </font><font style="text-decoration:underline;color:#000000;">https://www.takeda.com</font><font style="letter-spacing:0.5pt;font-family:Century;font-size:10.5pt;color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Neurocrine Biosciences Forward-Looking Statements</font><font style="Background-color:#FFFFFF;font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the benefits to be derived from transactions with Takeda Pharmaceutical Company Limited<font style="font-weight:bold;">; </font>our potential milestone and royalty payments to Takeda; the development of our product candidates and the timing of completion of our clinical, regulatory, and other development activities. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions; risks and uncertainties related to any COVID-19 quarantines, shelter-in-place and similar government orders that are currently in place or that may be put in place in the future, including the impact of such orders on our business operations and the business operations of the third parties on which we rely; our future financial and operating performance; risks or uncertainties related to the development of the our product candidates; risks that the FDA or other regulatory authorities may make adverse decisions regarding our </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:8.52%;"><font style="margin-left:41pt;"></font>3</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">product candidates; risks that clinical development activities may not be completed on time or at all; risks that clinical development activities may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for a product candidate; risks that the benefits of the agreements with Takeda may never be realized; risks that our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2020. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Takeda Pharmaceutical Company Limited </font><font style="color:#000000;">Forward-Looking Statements </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda&#8217;s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as &#8220;targets&#8221;, &#8220;plans&#8221;, &#8220;believes&#8221;, &#8220;hopes&#8221;, &#8220;continues&#8221;, &#8220;expects&#8221;, &#8220;aims&#8221;, &#8220;intends&#8221;, &#8220;ensures&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;could&#8221; &#8220;anticipates&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221; or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda&#8217;s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda&#8217;s operations and the timing of any such divestment(s); and other factors identified in Takeda&#8217;s most recent Annual Report on Form 20-F and Takeda&#8217;s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda&#8217;s website at: <font style="text-decoration:underline;">https://www.takeda.com/investors/reports/sec-filings/</font> or at <font style="text-decoration:underline;">www.sec.gov</font>.&nbsp;&nbsp;Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda&#8217;s future results.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;line-height:17pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:109.11%;"></table></div>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:109.11%;">
<tr>
<td style="width:109.11%;"></td>
</tr>
<tr>
<td style="width:109.11%;"></td>
</tr>
<tr style="height:15.4pt;" style="height:78.25pt;">
<td valign="top" >
<p style="line-height:17pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="line-height:17pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk42182859"></a><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contacts:</font></p>
<p style="line-height:17pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="line-height:17pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Neurocrine Biosciences, Inc. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Takeda Pharmaceuticals</p>MediaNavjot Rai+1-858-617-7623media@neurocrine.comInvestorsTodd Tushla+1-858-617-7143ir@neurocrine.comMedia in JapanKazumi Kobayashi+81 (0) 3-3278-2095kazumi.kobayashi@takeda.comMedia Outside JapanMonique Kelley+1-857-600-3488monique.kelley@takeda.com
<p style="line-height:17pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:8.52%;"><font style="margin-left:41pt;"></font>5</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gcjj3cauwzyv000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcjj3cauwzyv000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U -4# 2(  A$! Q$!_\0
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M=7^1NT5Q$'Q.TRXTR[OULKP1VK1JRD+D[R0,<^U)_P +2T/['#-Y5UYLKE1
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MEX?\ RO9:39F_P!:3Y9+F<<1GT_^LOYU)%<:A=1"?4[EYKJ3YF!X5/\ 94=
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M]3'$QYIMO?8N>"GR4E%*\;7.*^%-C:WNO7375O'-Y5ME!(H8 E@,X/>L3Q'
MUIXVU*'3D\HK,XC2,8P"O('X$UZSX1\+:)HS2:AH]Y+<I.GE[VD5U(![8 [B
MGMX%TMO$O]O&6Z^U>=YVW>-F<8QC&<?C5_6H*K*72QD\OJ.A&GU3U/,_ MMK
M$[7G]BZK964P"[Q.H+.O/3*GCUK;\*:,]MXXCO/[?TFYN"TGG0VS'<^0<X 4
M#KS^%;^I_"S1+ZY:>WDN+,L<E(B"GX CBMCPYX-TKPR6DM%>2X==K3RG+8]!
MC@"E5Q,))N+W\OU*H8*K"48R6D7O=_@CH:***\\]D**** *][:1WUG);RCY7
M'7T/8UPUE;/;>(;:WG4;XYP#_0UZ#65J.F>=J5E?1+^\BD D]U]?PK"M2YFI
M+=&M.=DXOJ<IJ=NT_B*Y@A0%Y)L #U('-=O864>GV4=O'_"/F/\ >/<U2L=,
M\O5KR_E7YW<K$#V7 R?QK6HHT^5N3W85)W2B@HHHK<R"BBB@"E::5:V-]>W=
MNFQ[QE>8#H6 QGZGO537/#EKKT]A+<RRH;*;S4\LCDY!YR/85L44VV]Q))*R
M*MU8Q7=Q9SNS!K24RH!T)*,G/X,:S]9\-V^M7"RRSS19B,$RQXQ+$6#%3D''
M*CD8-;5%(9G:UI":U8K:O/)!MD6021@;U([J2/E/N.:=JVEKJEO"GGR02P3+
M/#*@!*.,@'!!!X)&#ZU?HH I7NF1ZAI@L;B60KF,EQ@,2C!@>F.2OI4.M:+#
MK45JDLKQFVN%N(V0 _,H(YSV^8UIT4 9VL:+::[:Q6UZK-%',LP"G&67..>H
MQG.1SD"F'0;1O#0T%FE:U%N+?<6^?:!@'/K6I10!4AM)%T\VMS=27+LK*\S*
MJDY]E  _*H=&TF/1M%@TR*5Y(H$V(S@9Q[X&*T:* ,[1=)31=.6SCGDF4.S
MN  N3G:H'"J.P'2M&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gcjj3cauwzyv000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcjj3cauwzyv000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z '<# 2(  A$! Q$!_\0
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M>R_4]V.&H4*GU; \LZJWE)JU^T4]&_OL=#HO@;0M%Q)':"YNNK7%S\[D^O/
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K8M%M XZ%DW8_/-;M%/V4.R$\=BFK.I+[V(    , = *6BBK.4**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nbix-20200612.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-06-15T16:45:11.1359980+00:00 -->
<!-- Version            : 5.0.1.463 -->
<!-- Package ID         : f119af81f994498bbd392498592b9f45 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nbix="http://www.neurocrine.com/20200612" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20200612" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.neurocrine.com/20200612/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20200612_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20200612_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nbix-20200612_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-06-15T16:45:11.1359980+00:00 -->
<!-- Version            : 5.0.1.463 -->
<!-- Package ID         : f119af81f994498bbd392498592b9f45 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nbix-20200612_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-06-15T16:45:11.1359980+00:00 -->
<!-- Version            : 5.0.1.463 -->
<!-- Package ID         : f119af81f994498bbd392498592b9f45 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/20200612/role/TemplateLink" xlink:href="nbix-20200612.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="nbix-20200612.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>nbix-8k_20200612_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20200612.xsd" xlink:type="simple"/>
    <context id="C_0000914475_20200612_20200612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-06-12</startDate>
            <endDate>2020-06-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000914475_20200612_20200612" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000914475_20200612_20200612" id="F_000004">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000914475_20200612_20200612" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000914475_20200612_20200612" id="F_000002">2020-06-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000914475_20200612_20200612" id="F_000003">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000914475_20200612_20200612" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000914475_20200612_20200612" id="F_000006">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000914475_20200612_20200612" id="F_000008">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000914475_20200612_20200612" id="F_000009">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000914475_20200612_20200612" id="F_000010">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000914475_20200612_20200612" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000914475_20200612_20200612" id="F_000012">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000914475_20200612_20200612" id="F_000013">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000914475_20200612_20200612" id="F_000014">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0000914475_20200612_20200612" id="F_000019">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000914475_20200612_20200612" id="F_000020">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000914475_20200612_20200612" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="C_0000914475_20200612_20200612" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000914475_20200612_20200612" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000914475_20200612_20200612" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000914475_20200612_20200612" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000914475_20200612_20200612" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " !,.=!0]1%00.X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/:L,P#(=?9?B>R$DA8R;-I66G#08K;.QF;+4UC?]@:R1]^SE9
MFS*V!]C1TL^?/H%:%83R$5^B#QC)8+H;;>^24&'-CD1! "1U1"M3F1,N-_<^
M6DGY&0\0I#K) T+->0,626I)$B9@$18BZUJMA(HHR<<+7JL%'SYC/\.T NS1
MHJ,$55D!ZZ:)X3SV+=P $XPPVO1=0+T0Y^J?V+D#[)(<DUE2PS"4PVK.Y1TJ
M>']^>IW7+8Q+))W"_"L90>> :W:=_+;:;'>/K*MYS0O>%%6SX_>BXH(_?$RN
M/_QNPM9KLS?_V/@JV+7PZRZZ+U!+ P04    " !,.=!0F5R<(Q &  "<)P
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MAM^-&.Z-XP1TF^2$9QC@\)(SC,C]AJ&2IL9!+UYX7_Y%+?P.S/\"4$L#!!0
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M @  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSK9)!"H,P$ "_(GE
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M+GAM;%!+ 0(4 Q0    ( $PYT%#U$5! [@   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $PYT%"97)PC$ 8
M )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ 3#G04&)W'TJA @  DPL  !@              ( !]P@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $PYT% 0/_7)9 (
M  T&   4              "  <X+  !X;"]S:&%R9613=')I;F=S+GAM;%!+
M 0(4 Q0    ( $PYT%"ZH3F*UP$  #(&   -              "  60.  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ 3#G04##_Y')$ 0  / (   \
M         ( !9A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $PYT%#_
MP"8(O0   (4"   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( $PYT% +C]@#(0$  %<$   3
M      "  <P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     *  H @ (
' !X4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001564590-20-029427-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-029427-xbrl.zip
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M.TJT62IMH%8'6OJZ%6WOTNM?[?V+]C+<[;?KG79?KK?J6^/Z7U!+ P04
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MW7%!RJ#_%$CVQ*T\4O_O)SF%X_^!\^E_4$L#!!0    ( $PYT%"4'T.&_ 0
M .(K   5    ;F)I>"TR,#(P,#8Q,E]P<F4N>&ULY5I;C^(V%'ZOU/_@S;[L
M:IL;E^D$#;NBS,P*E9E!0-M57U;!<< :QT9VN/W['@="8$AV8+>I*H4'",FY
M?/Y\<GQ.XIM/ZXBA)9&*"MXV7,LQ$.%8!)1/V\9"F;["E!I(Q3X/?"8X:1L;
MHHQ/'W_^Z>:-::+;^]XCZN"8+LDM59@)M9#DW>CA/?KRV["/^I0_3WQ%T*W
MBXCP&)EH%L?SEFVO5BLK""E7@BUB\*XL+"(;F69JNBN)KR^@6S\F*/FT4,VI
M.:9S9;K-L7O5:C1;KFNY]:;G73L?'*?E. <&_MP."QU\6JAI.99K-:[J!X(#
M'S_[4X)ZMP>"H>MZ?GCMAI[7:'C7DTE0]VIPT/1J$R]L- ^1BOE&TNDL1N_P
M^P0BC)=SPAC9H'O*?8ZIS] H'>DOJ,>QA3J,H:%64VA(%)%+$E@[JPQX:[&4
M/)@CKI*_;>. O?5$,DO(J5USG+J=2AL[\?6)_*J>2+N>Y]G)U;VHHGF"8-:U
MOSST1WA&(M^$J8(HP-J!HBV5G.P+G,S1&;A0H83^9Z9BICYENC6S[EIK%1C
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M8;,!?QPW&_WFX.@XN5)_,A5\. K(OOU&+1'VZWG,==F4?.(>]6Q.7=*+=GH
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MUHF;1JH2T1BSVI9=\>J.C]W?=Q+EQZ&HS9F^.RFR?5+$*C):HOO15KX'*%=
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M0?MKKT*/GYT:0T:X.8?=,M>?J-U2SU&9 B8P2L3_'1<I(9'XH50Q)C_T' E
M5+$M*3&&E*Y3DO@%4 *O6"#)/OJ$&$."6:8'Y#' Z9!OPG=".Y"9/;7(/G]#
M;LY_K9P=6FJ#TA[Q?_N3D6 >IP]$)N '4-GMDG/<68Z.][F9^^3X4 -7,!H@
M6"N"28YAM@" /<'+]Q"J#UM,-!% 8BCHN&@U9CGU(PT*ZHV8XS\<#-&8A3,K
M"@K\H<Z#*.K&R3*K?2 9Q(BX9M29:G1D2>% K62?WR*AAP*$FU>Q7>XIU@)<
M#%E,H ]:RR6,VX[&+5Q)M:P*[[$S8<F%/4Q[K* K#$O")O-!W:3ZV?OP6YQ8
MS$G% Q).@"-TC'O"A1$[T)J),?=B*40G$]B<BE7=45VCHN/?4M.=BJ3;C$]4
M,@N%IV#_"CG*>E71"7ZLQ&%MEU'8':B91+KS;U0$E9X-6*A<^PY>K'V.^1H1
MRH!TQ]A;K361ASL].<#L'1WKJ/R^#.T1P<\.I^E[&5L4S*;!0$O)I)9<"-0D
MVZGIXZT=K#C_;+/M:(@5%P$\9S09YC H(E<5Q XQKZ$@%64/4EL]P-.26O\>
M*#;5A,<$XOD =M5W%;THM.L_ 6\PKLU$0+DB##UO?.L?EN,JI1-B\9+P@4@"
MH 7<+KXDU'7)@#/744O"] K0%R5WOG"=.^XPTJ<@L'$.HQP/"'!*.* PHF Y
M+<F25.T8*6#2(E$$=IG4VXL6!"#:!UQ;$%]\*4D/K!EDT*N)JCA80D"<EQ((
M/DMK7U M@,,^6B_ E<#>1/A3Z@;32I_I>2?:1$@P>-ZX2^:Y]#%=;!<97M$4
MH+!!.DF.]*<4*3RV?1EHH0,"2U,DJ!/?QHIQ9Z;W$K;5?!**19QB8J69%.G_
M@><<$K0.K,(T0+6",PP7+96Y?*C6"5V4)+R=9]\1( ,F T"JWHH&(=8%J W@
MOLWTLU61?;JB8+DVB/EH$&-LM]6%2W:_@BF0**F/$^)"_0FR U$1@HFF2&D(
MD0J!*<LE$)^="'0(X'RJ1F+$3(E"A0:&TF >#4(72%_=8.@J0DB!;B%"X:?+
M68ADH)&GBC#+<+0R(C2'5GIJ%VMB(275>K/MR/AKU+;O.=QLR !Q3*<ZI8TM
MV3T2'["A HS!E\9?Y)%D6+W/X 5+84@%? #" ).X=9?$]EV@ D/*_L=)TN.E
MME N<]0Y?O.NT.#,BZ B "]-M7X81-/-(=QX3YH9\W2<>'GGAZX#"P2&!X%#
M2OBPNB26<'U&@V:E RT$$.$@9QS$$K#.S#G$#:I*!98\ ",9TLULG(6H3$R4
M0F@7%+FC"?# R/Z(U6PN['",?IB=9M'EO&"*U*'+IJ /X!T$ &I%&*,_35)G
M,=VOAN,28DJP@F&!R#)>@@TF$<*?UQK93&57@GL+7+28=TN80FZW:2 7J)+J
M:S8T+Q*<^LV%'@IB%QQ,'XP<DJOX=!W 8;%>FXF.3X! )?6S8:8# UKEPF!@
MXPXEHW%P#.]/P'M$T0!XN!/*-3THI)A)],D%=YJC'B-0E#R UBF1% N?E+2[
M2<RL316)604N@5#('S[X0;!YQA1I(TWA2266CG@LGRE)0^Z77GM5XP$ 0HWE
M/O9!?*F@E!.5G1$L@ O8D-L$7&TAE7(T+)R0O7/L^>H/(-ANLC2%WNM,7"BJ
MHM+WE+?,!C!>D'1D=:" L>]8<AB"!O3%-(Z-X$L=T8CC+ =(L+:BR*@14BJ&
M60&5+DP%./)8CF4TJE'/"RY39EK*1,#5K#O.N;:I4?"IBQKA\>R7H9O?/!4Z
M5]^U J'Y"P6X:;[LA!@6 +J%)F@J1/$CT^-7V++CCQ\8'/Q*_P!@Z6/JV;"@
MB4^N#LB\.DOM^BYIC-\ (3.,Z%#EENPG:LWU$>$"^*66D]S!LP4R-\-8:4]:
M^BXK$-%HI>)):V/((K1];^@KTZ'8=I7$#@7>SP>C]9D6Q&H,K3O,M.LG=^)I
MK\PZ;M2LA8DF&-I7%@)*A$&(W(Z&K:<]7!/UBBV4V)Q5/K$QJJ%9Z485J:*Y
MZH'W*B4%T8+>@7.+%G>19P=OR\S6M(E3Y%Y64V[5DF+0P#Z]F#3DM%""(1-6
M6]PT0G:)/G[-=M>GN'C\AHGQ$K85F47\,8X?>]H%X?^DI90.'D]HS",P6S@9
M"!_C-W2JS"(8\4]6HUZM8YC$55DU,)]"?=Z&"@_,(30UV!03;[[$^*0KE/Z9
M4)[UVW Z/95F%Y"% XP']$,)$E."Z*13&!F+@PLB!E62<CVS@3F,KKMZ2TF[
M+A'=P4CT!-__Z:AYG-B1"1;0(<!DB"<(RH-XLR&LZA'IEPV @JS,\<F9ERFT
MN-(OQLTL+*47, (BJX"MJ0XHX!4]F' 3*F(#4@:ZJX2/I"YZTQRL/11$@U Y
M0!Y(!OT&]E.Z3N!:4(;J%(.85OK3BODS,BFQ%3Z.XL!*N!U$8>*(@J2)DD1G
MY8A)0PVXD$$2RK@@[6B7K$A;$"9?%8^#,0:!_=!BRN:W!J:)1((.]"F]6VVL
M*U^O;"9 J,[UZ!V;U#,EGOHZ$(X[A1Z2 *^,Y^]FE6DB@Z5P(PEK,LKF\& Z
MC])RPZ_LE<2A92605HYD/G,89",R^V:6/UU*7KLHY@!/+F>SY"MS#DKR)TJZ
MX<$UD+DFAY:U7Y$%<S:MEF YSM7V!QY+<G6(Q#"2BK\<*!;2A0S3,J+2"TV2
MA3Y/A;2JSU<F2>[//QTWW\[L\&CLHLC;@0ZC^<3U4?O+E-Z((%">,=2GLQ()
M0[6,'%SFU,HLQQ!K,4*9Q,?PY4R@%5. L8EOF:?*MA#"F I!=2<8H !>8X;6
M4R 88^QROQ\&ZF ;F%CQ>;*4HX0HE_P>%7<PDB:IJZ(J>,T*=.4VF^EJ11:Y
MB#309:Y8"%U9S##X\V7B[&4./[A;'0PLZ6V#K0]*1GG(2R\+ +18%*G#1(]Y
MK.H'/@CUB*)^@[)](8,GN6[(L20O$PY(\<,G1='M&47W%O-#)$^3X^XS^69)
M1DE)GA4%76HGJU;+C!F&C7%C0^&#P8IV72%K*H]6IWUI'&<?,SS\RN58]5.G
M8[=2AEJ-QQ>AZ3S>5LG0A>3^\+6O2^]I\I@E!Q=0QL(0B+:)S!GRV!H9 8B8
M-V2:PO'LEL,U&3$/%FHS"IZA>C*(:=HL:F[A5(019><E08 V7/)WY&L9QQ.K
M@4T<,[E.QX<5(A%',1G-+^941]))SEA/N71LCD14U70&=\:CS^'/I%M3X$5K
M#JN==7%AE20*'2B&\YAY<T 85X6NF(-9CME3,#%%BO&F4>NBI6N"C]E]J4K:
MY-*5/YJ/&*=J 3*#F[RW9K"LI%EB<1J/9I!2?JR23A8P*G:P$#J#5#(-Y6ZH
M8WB80>\K4BTH5(R0:S7J.D@3?1PT=?(@CO%'PX_H+=-B5(<T9KD[70*!MRWH
M<0JF=%3,YP?).&'5@0Y\.DS:@D^2 8SYP;T9GT]",?%%8*HG3 V(Q@JX?1B!
MU@R8I<H^!G,'3"CE&%GO(9 =;F).4!&C0Q,EY30[1+&X 7>3B?C$=3BXE/AJ
M"S2%N"[5ISJ@>#_B?1YS8CNZ+,84G?X]!+)B OCVFJE]0D=U5:Q5K_P]KFTR
M]W7HBF%URN:PKD_9S$O:EUC_:U'1)LZ$ 1SNJ' J7WS_N_IN$B;D=/QMSJY?
M_$&J&[PNJ:W3/UFJP N$4=6 2).1ES\P8'(-F&0,ILAR-8(.*0F-6'6;\""^
MHZ5Q>C[_WJADO;K.><9=K<Z2]T,EQZ@2D Y8)3;#IU8-.L&D8A]*FVC>XMZM
M[X+,_>[Y=YYZ$GKZ;\'E=XD%6\8@B=E1U5L0C*/X0AI&1G5BT^A6G"P?4FV]
M@-X,7:R4,5452FBCJK='G$6E_%H412H.6-?A R5I AT\105HME$TGLP-R.[5
M^1[@;52O(.'XK$2D'+LJ=R"Q3 ^SL##'U _A3Y"#2,1\,)W35XVN)+"I#XJ(
M":!DJ"8^"H 2,/M,CC  GGUJ%SV\*WJ(14YV3*#QXPE6YF0? G=P+'X!TR'[
MJL]<A&+N.9,!'Q=U .OTC\*)!7-XT7,?(^R Y=21"0YR@(H(;>IJO.1=WDO
MOY %!KKJKX Z33*8W')VE[=<\RR#)I#.F"@]),.Q+O$R)SYBNU0QD&&I! ]5
MR6?E"@5JC:E7FLHT^K5^=JF-;9P0J=WE=)8/D?.I]QQLNX.%[6!0A+)V!O*0
MB3&M]YW8JN^YT\3Q$1T6-I?1E4O7UZQ/U24OS6K=JI)96C:A5+4AH\R5TF+
MI[@$_C!_YY4YW;[N#4-Z[A8- __M VX;RGR;)&K_\Z-\4N^1 3J9_QF[LZ<]
MO*^(9KDOO!@HS@=B^1<JGPIL,916^UZ-N82JN0Y-O"(*N)@Y>&M\J3#/6 B!
MK>6J!%"SWZ]8@?R?D:S77662K)?$R); ?V7"VQ1=;<;%;#:KUO:2ZX8^4+8>
M?SPY7,!>\47KI_KQR6';VB24WE$R$GC1L-?G]Q5VWVQ:_[1.JZ-@G$DKJC$=
M9ONZTJ>EBN_QMD]]Q;B48'=CL; VRDU RSK1 :TX-DJ+OLD5Q EG<W'H4;49
M?^AMZ_F\\2*TQ;JK?!9N6+S,,DH!4CU^.:3R[-QMU8^VER1W&F%+X-+&4E/R
M#>MRN\@$-"YEIN03=]F:GW9X\3%[<^/U\O]=$&72-[* N1N,MJI^*R$%%1H6
M"\%YT:ZE*KR>HIRKE!C7OUL]2WUEU6-KZ)%MB1_VNI\OSV]^N^[T'K/D\+E9
M]5OBC+:^^TE=]J1#H,LFLX+\YQ><T#4))D<'F05+)*XE(%R'XS%+W6<CZ@ZB
M%(^RCTT#3%RQ$*\85./1,!CY N#DK!Z0G0_REQ!P[5/[.];:>4[%>$&?U+_\
M[9SI;T3K"$7J(]&91Q]G4-.+.LXI[J)+1DLN%2V\0;3XPM"5S8%RAU"'7S9N
M)"UG'CTC*G.FZ0Z3:V$25H>N^/N]QMX68/5PA]55L7K9^>WZJGW=O>R0C]VK
M7KO;N6QW>@>D>]FNKA$LW4GCK<;V3AKO,+F3P#M,+H/)TQTJ'X[*C:G-F8Y<
MKX1BA^R%Y0PT8*UL7FHS3/S <ID=KK=;1L>J]96A=TZT:>M4X>J56UL+]JWA
MJIJL:8Q?X%4+Y&N5?.&3B>\ZP5:HT)WG^6HDZ,[S?/68?#F>9RXW]S#4OC8\
MGJY<3[JUF-X:GMTIV%>/XBUEYYV"?2V8W"G85X+'76!W]9+&$6<#\H4-J4NN
M!@-N,[%&%>,CE>$4E8DA$#,03Q99+9YGQ:+ 9[]([EVM[SM3!>51,';AC_\'
M4$L#!!0    ( $PYT%!9:?X :!D   !_   1    ;F)I>"UE>#DY,5\Q-RYH
M=&WM/6EWVS:VW^><]Q\P[K1C=T1MWF0YS1G%3E*_;'ZQT[[Y- <B(0DQ1;
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M0282:WB(A.*Z('@8JKEAJ5E&^#"588!6,\Z)7.0& \FS)&L"X$5@<S9*DQ1
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M(K9FC O-PP@QN-JV/ZZBHUQA((%9TKJT71,^PV@^9D(CG,-@IYW=47@@5V0
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M G";Z=6$,N2%YT NQ>BZ./AU#H4[B<CM^_IQ9%*$+QLH-[##GN,PCGI!UH,
M)$V7*/^B)%K24#39*1X,4@K(8D$%+HQ'>53?^OK.LLK53DZ\I8! Q=PICDRJ
M75LIU. FL:$&&Z#/60@/P7:*?&&9-=C81MF%<,+LH[,\BTF7S4,'XZ-JH7-?
MHG4WW\_V,(["#PS^N[NOZ'(XNOZ;/PZ:G0[%CM=]J\'G1^7+D6?\7,4R7GB
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M2P$"% ,4    " !,.=!0:= X""('  "720  %0              @ 'D!
M;F)I>"TR,#(P,#8Q,E]L86(N>&UL4$L! A0#%     @ 3#G04)0?0X;\!
MXBL  !4              ( !.0P  &YB:7@M,C R,# V,3)?<')E+GAM;%!+
M 0(4 Q0    ( $PYT%#HBGKP8QX  "0# 0 4              "  6@1  !N
M8FEX+3AK7S(P,C P-C$R+FAT;5!+ 0(4 Q0    ( $PYT%!9:?X :!D   !_
M   1              "  ?TO  !N8FEX+65X.3DQ7S$W+FAT;5!+!08
..!0 % $8!  "420     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-8k_20200612.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nbix-8k_20200612.htm">nbix-8k_20200612.htm</File>
    <File>nbix-20200612.xsd</File>
    <File>nbix-20200612_lab.xml</File>
    <File>nbix-20200612_pre.xml</File>
    <File>nbix-ex991_17.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-8k_20200612.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-8k_20200612.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20200612_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20200612_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20200612.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20200612",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-8k_20200612.htm",
      "contextRef": "C_0000914475_20200612_20200612",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-8k_20200612.htm",
      "contextRef": "C_0000914475_20200612_20200612",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200612/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6647269728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 12, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 12,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
